BioSpace News Archive

CollPlant Biotechnologies (NASDAQ: CLGN) today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update on its programs.

Willow Biosciences Inc. announces that having completed its transition to the San Francisco Bay Area and the commercial focus on its BioOxi platform, it has engaged an advisor to assist the Company with a review of opportunities to enhance shareholder value and unlock its intellectual property portfolio.~

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has achieved key milestones in its R&D collaboration with Labcorp, a global leader of innovative and comprehensive laboratory services, aimed at driving innovation in the development and validation of cell and gene therapies.

Societal CDMO, Inc. announced the pricing of its previously announced underwritten public offering of 20,750,000 shares of its common stock at a public offering price of $0.40 per share of common stock, for gross proceeds of $8.3 million, before underwriting discounts and commissions and offering expenses.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce it dosed patients in a Phase I/II clinical trial, evaluating the safety and efficacy of its lead anti-infective candidate, RECCE® 327 (R327), for the treatment of diabetic foot infections (DFI).

aTyr Pharma, Inc. (Nasdaq: LIFE) today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place September 11 – 13, 2023, in New York, NY.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) today announced the U.S. FDA has granted Fast Track Designation (FTD) to TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the company expects to resubmit its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease in adult patients on dialysis by the end of the third quarter of 2023.

Endologix LLC is pleased to announce that Lucas Buchanan has been appointed to the Endologix Board of Directors.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the phase 3 CABINET pivotal trial early due to a dramatic improvement in efficacy that was observed at an interim analysis.